Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VULUJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TQB2101
|
|||||
| Synonyms |
TQB2101
Click to Show/Hide
|
|||||
| Organization |
Chia Tai Tianqing Pharmaceutical (CTTQ) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-ROR1 antibody
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Colorectal cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Unspecific non-hodgkin lymphoma |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|